Compare LRHC & SHPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LRHC | SHPH |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9M | 2.9M |
| IPO Year | 2023 | 2022 |
| Metric | LRHC | SHPH |
|---|---|---|
| Price | $1.15 | $1.68 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 317.7K | ★ 364.0K |
| Earning Date | 11-19-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $78,660,186.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.52 | N/A |
| 52 Week Low | $1.05 | $1.26 |
| 52 Week High | $95.20 | $25.25 |
| Indicator | LRHC | SHPH |
|---|---|---|
| Relative Strength Index (RSI) | 21.66 | 37.77 |
| Support Level | $1.05 | $1.65 |
| Resistance Level | $2.25 | $2.04 |
| Average True Range (ATR) | 0.27 | 0.20 |
| MACD | 0.08 | 0.08 |
| Stochastic Oscillator | 5.00 | 46.36 |
La Rosa Holdings Corp operates in the U.S. residential real estate market. It is a holding company for agent-centric, technology-integrated, cloud-based, multi-service real estate companies. The company's business is organized based on the services it provides internally to the agents and to the public, which are residential and commercial real estate brokerage, franchising, real estate brokerage education and coaching, and property management. The company has six reportable segments, namely: Real Estate Brokerage Services (Residential), Franchising Services, Coaching Services, Property Management, Real Estate Brokerage Services (Commercial), and Title Settlement and Insurance. It derives maximum revenue from the Real Estate Brokerage Services (Residential) segment.
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. It is developing a pipeline of products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of RT. The company believes that its product candidates will enable the company to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.